Efficacy of artemether-lumefantrine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso, 2020-2021.

ABSTRACT:

Background

Burkina Faso has conducted regular therapeutic efficacy monitoring of artemisinin-based combination therapy (ACT) since its introduction in the early 2000s. Since 2008, artemether-lumefantrine (AL), the most widely used ACT to treat uncomplicated malaria, has shown reduced efficacy in Burkina Faso. To inform national case management policy, investigators conducted a therapeutic efficacy study in 2020-2021.

Methods

Children aged 6 months to 12 years with microscopically confirmed uncomplicated Plasmodium falciparum malaria were enrolled in three sites, treated with either AL, dihydroartemisinin-piperaquine (DP), or artesunate-pyronaridine (AS-PYR), and monitored for 28 or 42 days to determine treatment response. Dried blood spots were collected on filter papers to

SUBMITTER: Gansane A 

PROVIDER: S-EPMC12777320 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature